Document Detail


Cardiogenic shock from left ventricular dysfunction complicating an acute ST-elevation myocardial infarction.
MedLine Citation:
PMID:  19742431     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Cardiogenic shock from left ventricular dysfunction complicating an acute ST-elevation myocardial infarction is associated with high mortality. Much of the current understanding of the importance of emergency revascularization comes from the SHOCK trial. Mortality benefits combined with improved quality of life among the survivors justify the routine use of emergency revascularization in patients <75 years of age and in selected patients >or=75 years of age. This article discusses the SHOCK trial and potential mechanisms of benefit from revascularization as well as more recent information. Adjunctive therapies have been disappointing. To further improve outcomes, earlier pre-emptive and preventive strategies to ensure early revascularization should be pursued.
Authors:
Cheuk-Kit Wong; Harvey D White
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  The American heart hospital journal     Volume:  7     ISSN:  1751-7168     ISO Abbreviation:  Am Heart Hosp J     Publication Date:  2009  
Date Detail:
Created Date:  2009-09-10     Completed Date:  2010-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101156064     Medline TA:  Am Heart Hosp J     Country:  England    
Other Details:
Languages:  eng     Pagination:  33-8     Citation Subset:  IM    
Affiliation:
Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty
Coronary Artery Bypass
Hospital Mortality
Humans
Myocardial Infarction / complications*,  mortality,  physiopathology,  therapy*
Outcome and Process Assessment (Health Care)
Quality of Life
Randomized Controlled Trials as Topic
Shock, Cardiogenic / etiology*,  mortality,  physiopathology,  therapy*
Survival Rate
United States
Ventricular Dysfunction, Left / complications*,  mortality,  physiopathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro inhibition of platelet aggregation in response to increasing concentrations of tirofiban in...
Next Document:  Non-invasive risk stratification for implantable cardioverter-defibrillator placement--heart rate va...